RONALD W. HART, PH.D. - Corporate Board Profile

GUIDED THERAPEUTICS INC

Filing Date	Source Excerpt
2008-11-19	Ronald W. Hart, Ph.D. has served as a member of our board of directors since March 2007. ... Based on the definition of independence of the Nasdaq Stock Market, Mr. Zachary, Mr. James, Dr. Hart, Dr. Imhoff and Mr. Allen are independent directors.
2010-04-20	Ronald W. Hart, Ph.D. 67; has served as a member of our Board of Directors since March 2007. He is Chairman of the Nomination Committee. Director compensation table shows option awards of $7,600 in 2009.
2011-06-30	Ronald W. Hart, Ph.D. has served as a member of our board of directors since March 2007. He has published over 600 peer-reviewed publications, has been appointed to a number of academic positions and is credited with developing the first direct proof that DNA is causal in certain forms of cancer. He chaired a number of federal committees and task forces, including the development and implementation of the Technology Transfer Act of 1986 and the White House Task Force on Chemical Carcinogenesis. In 1980, Dr. Hart was appointed Director of the National Center for Toxicological Research, the research arm of the FDA, a position he held until 1992. In 1992, Dr. Hart was the first ever Presidential Appointee to the position of Distinguished Scientist in Residence for the US Public Health Service/FDA, a position he held until his retirement in 2000. Dr. Hart received his Ph.D. in physiology and biophysics from the University of Illinois. Dr. Hart currently serves on the Boards of Directors of Miltos Pharmaceuticals, WaterChef, Inc. and Immunovative, Inc. and since 2002, has helped in the development of business strategy for a number of start-up companies. Dr. Hart adds considerable value to our board in at least four critical areas: (1) As a former FDA bureau chief, he advises the board on our FDA relationship and strategy. (2) As an active participant in the venture capital community, he advises the board on financing and other opportunities. (3) As an expert in organizational matters, he advises the board regarding corporate strategy and potential strategic partnerships. (4) As an expert in international trade, he advises the board on international partnering and distribution agreements. The nomination committee, in consultation with our Chief Executive Officer, reviews and recommends individuals to be nominated as directors. The nomination committee currently consists of Ronald Hart (Chairman) and Ronald W. Allen. The nomination committee was formed on February 26, 2010.
2012-04-30	Ronald W. Hart, Ph.D. 69 Vice Chairman and Director... He was elected Vice Chairman in [month] 2011... The nomination committee currently consists of Dr. Hart (Chairman) and Mr. Allen.
2013-04-26	Ronald W. Hart, Ph.D. has served as a member of our board since March 2007 and was elected Vice Chairman in October 2011... The nomination committee currently consists of Dr. Hart (Chairman) and Mr. Allen.
2014-05-13	Ronald W. Hart, Ph.D. has served as a member of our Board of Directors since March 2007 and was elected Vice Chairman of the Board in 2011. The compensation committee currently consists of Dr. Imhoff (Chairman) and Dr. Hart. The nomination committee currently consists of Dr. Hart (Chairman) and Dr. Rosenstock.
2015-04-27	Ronald W. Hart, Ph.D. has served as a member of our Board of Directors since March 2007. ... The audit committee currently consists of Mr. James and Drs. Niloff, Hart, Imhoff and Rosenstock. ... The compensation committee currently consists of Mr. James and Drs. Niloff, Hart, Imhoff and Rosenstock, each of whom is independent under NASDAQ listing standards. ... All of the members of the board of directors, with the exception of our Chief Executive Officer, serve on the audit, compensation and nomination committees.